The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir–lamivudine–dolutegravir in South Africa: a modelling study

作者：Emily Parker Hyle, Linda‐Gail Bekker, Suzanne M. McCluskey, Wanyi Chen, Paul Edward Sax, Mahomed‐Yunus S. Moosa, Munashe Machoko, Audrey C. Bangs, Kim Steegen, Mark Jacob Siedner, David A. M. C. van de Vijver, Stephen Resch, Anne M. Neilan, Andrew N. Phillips, Rochelle P. Walensky, Richard J. Lessells, Milton C. Weinstein, Caitlin M. Dugdale, Robin Wood, K.A. Freedberg · 发表于：The Lancet HIV · 年份：2025 · DOI：10.1016/s2352-3018(25)00164-x · 被引用次数：5 · 研究领域：HIV/AIDS drug development and treatment、HIV/AIDS Research and Interventions、HIV-related health complications and treatments